Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc. (ACTU) priced its initial public offering on Aug 13, 2024 at $8.00 per share, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $152.9M. Newbridge was lead-left underwriter. BakerHostetler advised the company and McGuireWoods advised the underwriters.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 (GSK-3). Its candidate is elraglusib, a small molecule that blocks GSK-3 beta in cancer cells.

Status

IPO

Ticker

ACTU

Exchange

Nasdaq Global Market

Priced

Aug 13, 2024

IPO price

$8.00

Market cap at IPO price

$152.9M

First filed

May 24, 2024

Underwriters

Newbridge

Company counsel

BakerHostetler

Underwriters' counsel

McGuireWoods

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.